323 related articles for article (PubMed ID: 17096589)
1. Direct inhibition of T-cell responses by the Cryptococcus capsular polysaccharide glucuronoxylomannan.
Yauch LE; Lam JS; Levitz SM
PLoS Pathog; 2006 Nov; 2(11):e120. PubMed ID: 17096589
[TBL] [Abstract][Full Text] [Related]
2. Glucuronoxylomannan in the Cryptococcus species capsule as a target for Chimeric Antigen Receptor T-cell therapy.
da Silva TA; Hauser PJ; Bandey I; Laskowski T; Wang Q; Najjar AM; Kumaresan PR
Cytotherapy; 2021 Feb; 23(2):119-130. PubMed ID: 33303326
[TBL] [Abstract][Full Text] [Related]
3. Evasion of Innate Immune Responses by the Highly Virulent Cryptococcus gattii by Altering Capsule Glucuronoxylomannan Structure.
Urai M; Kaneko Y; Ueno K; Okubo Y; Aizawa T; Fukazawa H; Sugita T; Ohno H; Shibuya K; Kinjo Y; Miyazaki Y
Front Cell Infect Microbiol; 2015; 5():101. PubMed ID: 26779451
[TBL] [Abstract][Full Text] [Related]
4. Differences in outcome of the interaction between Cryptococcus neoformans glucuronoxylomannan and human monocytes and neutrophils.
Monari C; Retini C; Casadevall A; Netski D; Bistoni F; Kozel TR; Vecchiarelli A
Eur J Immunol; 2003 Apr; 33(4):1041-51. PubMed ID: 12672070
[TBL] [Abstract][Full Text] [Related]
5. Presentation of cryptococcal capsular polysaccharide (GXM) on activated antigen-presenting cells inhibits the T-suppressor response and enhances delayed-type hypersensitivity and survival.
Blackstock R; Casadevall A
Immunology; 1997 Nov; 92(3):334-9. PubMed ID: 9486105
[TBL] [Abstract][Full Text] [Related]
6. Regulated Release of Cryptococcal Polysaccharide Drives Virulence and Suppresses Immune Cell Infiltration into the Central Nervous System.
Denham ST; Verma S; Reynolds RC; Worne CL; Daugherty JM; Lane TE; Brown JCS
Infect Immun; 2018 Mar; 86(3):. PubMed ID: 29203547
[No Abstract] [Full Text] [Related]
7. A Glucuronoxylomannan Epitope Exhibits Serotype-Specific Accessibility and Redistributes towards the Capsule Surface during Titanization of the Fungal Pathogen Cryptococcus neoformans.
Probert M; Zhou X; Goodall M; Johnston SA; Bielska E; Ballou ER; May RC
Infect Immun; 2019 Apr; 87(4):. PubMed ID: 30670549
[TBL] [Abstract][Full Text] [Related]
8. Binding and internalization of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans, by murine peritoneal macrophages.
Chang ZL; Netski D; Thorkildson P; Kozel TR
Infect Immun; 2006 Jan; 74(1):144-51. PubMed ID: 16368967
[TBL] [Abstract][Full Text] [Related]
9. Receptor-mediated clearance of Cryptococcus neoformans capsular polysaccharide in vivo.
Yauch LE; Mansour MK; Levitz SM
Infect Immun; 2005 Dec; 73(12):8429-32. PubMed ID: 16299344
[TBL] [Abstract][Full Text] [Related]
10. High affinity mimotope of the polysaccharide capsule of Cryptococcus neoformans identified from an evolutionary phage peptide library.
Beenhouwer DO; May RJ; Valadon P; Scharff MD
J Immunol; 2002 Dec; 169(12):6992-9. PubMed ID: 12471134
[TBL] [Abstract][Full Text] [Related]
11. A cryptococcal capsular polysaccharide mimotope prolongs the survival of mice with Cryptococcus neoformans infection.
Fleuridor R; Lees A; Pirofski L
J Immunol; 2001 Jan; 166(2):1087-96. PubMed ID: 11145689
[TBL] [Abstract][Full Text] [Related]
12. The glucuronoxylomannan of Cryptococcus neoformans serotype A is a type 2 T-cell-independent antigen.
Sundstrom JB; Cherniak R
Infect Immun; 1992 Oct; 60(10):4080-7. PubMed ID: 1398921
[TBL] [Abstract][Full Text] [Related]
13. Capsular polysaccharides galactoxylomannan and glucuronoxylomannan from Cryptococcus neoformans induce macrophage apoptosis mediated by Fas ligand.
Villena SN; Pinheiro RO; Pinheiro CS; Nunes MP; Takiya CM; DosReis GA; Previato JO; Mendonça-Previato L; Freire-de-Lima CG
Cell Microbiol; 2008 Jun; 10(6):1274-85. PubMed ID: 18284419
[TBL] [Abstract][Full Text] [Related]
14. Cryptococcus neoformans capsular polysaccharide component galactoxylomannan induces apoptosis of human T-cells through activation of caspase-8.
Pericolini E; Cenci E; Monari C; De Jesus M; Bistoni F; Casadevall A; Vecchiarelli A
Cell Microbiol; 2006 Feb; 8(2):267-75. PubMed ID: 16441437
[TBL] [Abstract][Full Text] [Related]
15. The polysaccharide capsule of Cryptococcus neoformans interferes with human dendritic cell maturation and activation.
Vecchiarelli A; Pietrella D; Lupo P; Bistoni F; McFadden DC; Casadevall A
J Leukoc Biol; 2003 Sep; 74(3):370-8. PubMed ID: 12949240
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of HIV entry by extracellular glucuronoxylomannan of Cryptococcus neoformans.
Yi HA; Panepinto JC; Jacobs A
Microb Pathog; 2012 Jan; 52(1):25-30. PubMed ID: 21983597
[TBL] [Abstract][Full Text] [Related]
17. Peptide epitopes recognized by a human anti-cryptococcal glucuronoxylomannan antibody.
Zhang H; Zhong Z; Pirofski LA
Infect Immun; 1997 Apr; 65(4):1158-64. PubMed ID: 9119446
[TBL] [Abstract][Full Text] [Related]
18. Roles for CD40, B7 and major histocompatibility complex in induction of enhanced immunity by cryptococcal polysaccharide-pulsed antigen-presenting cells.
Blackstock R
Immunology; 2003 Feb; 108(2):158-66. PubMed ID: 12562324
[TBL] [Abstract][Full Text] [Related]
19. In vivo clearance of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans: a critical role for tissue macrophages.
Grinsell M; Weinhold LC; Cutler JE; Han Y; Kozel TR
J Infect Dis; 2001 Aug; 184(4):479-87. PubMed ID: 11471106
[TBL] [Abstract][Full Text] [Related]
20. Immunoregulation by capsular components of Cryptococcus neoformans.
Vecchiarelli A
Med Mycol; 2000 Dec; 38(6):407-17. PubMed ID: 11204878
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]